Another protein involved in the inhibition of the immune response against cancer cells, HVEM (herpesvirus entry mediator), was the target of a study in which linear and cyclic peptides were designed as antagonists of its interaction with BTLA (B- and T-lymphocyte attenuator). This evidence concerns the gene BTLA and cancer.